Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Radiology
•
Inflammatory arthritis
•
Nuclear Medicine
When would you consider utilizing bone scintigraphy in the assessment of inflammatory arthritis?
Answer from: at Community Practice
When it's a case of negative RA disease or when considering a neoplastic, gammopathy with myeloma...
Sign in or Register to read more
Answer from: at Community Practice
I would also consider using triple phase bone scan to assess the blood pool phase which may help determine sites of active inflammation. This may also help guide sites for intervention/injection.
Sign in or Register to read more
14606
22338
Related Questions
What is your approach to assessing inflammatory arthritis flares in joints that have been replaced (such as knees)?
Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?
What is your approach to monitoring patients referred for high titer +RF and +CCP but without active symptoms of inflammatory arthritis?
When considering a biologic for seropositive RA after failure of methotrexate or triple therapy, do you consider using abatacept as a first line biologic or would prefer choosing TNFi?
How do you approach managing nausea and GI side effects when initiating methotrexate?
How do you approach immunosuppression in patients with a positive Interferon Gamma Release Assay and prior intravesicular BCG treatment for bladder cancer?
What is the maximum dose of leucovorin that you use with methotrexate?
Do oral NSAIDs and steroids have an effect on how you interpret synovial fluid leukocyte count?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?